Need for Regulatory Change to Incorporate Beyond A1C Glycemic Metrics
Author:
- Beyond A1C Writing GroupBGBeyond A1C Writing Group
- 11 May 2018
- journal article
- letter
- Published by American Diabetes Association in Diabetes Care
- Vol. 41 (6) , e92-e94
Abstract
Hemoglobin A1c (A1C) is currently the “gold standard” in measuring diabetes outcomes. Substantial evidence, however, demonstrates the limitations of A1C in characterizing daily glycemic fluctuations and quality of life (1) or in accurately reflecting mean blood glucose levels (2). Data derived from continuous glucose monitoring (CGM) systems present a more comprehensive glycemic picture than A1C alone and are decidedly valuable as clinicians and patients seek to individualize therapy and make treatment changes accordingly. Concern about inconsistent reporting of CGM-measured outcomes has hampered progress in the field, as thresholds for these metrics often differ among trials. As a result, the diabetes community has developed consensus on key glycemic metrics to measure outcomes beyond A1C, which can be used in research, therapy development, and regulatory review (3,4). This report seeks to contribute broader engagement of the diabetes community and a specific focus on regulatory implications of achieving consensus on glycemic outcomes beyond A1C. To continue the push for consensus, The diaTribe Foundation convened a meeting, titled “Glycemic Outcomes Beyond A1C: Standardization and Implementation” (5), with leaders from nine organizations (American Association of Clinical Endocrinologists, American Diabetes Association [ADA], Advanced Technologies & Treatments for Diabetes, European Foundation for the Study of Diabetes, European Medicines Agency, Endocrine Society, U.S. Food and Drug Administration [FDA], International Hypoglycaemia Study Group, and JDRF). This meeting took place in Bethesda, MD, on 21 July 2017 and attracted key stakeholders, including representatives from about 25 companies, 15 medical and academic institutions, and 5 patient groups. This diverse group, in turn, engaged the dozen FDA delegates in a robust discussion and presented a unified case for the need to incorporate outcomes beyond A1C into regulatory decisions and clinical care. The Beyond A1C movement has gathered significant momentum, captured most recently by literature featured in Diabetes Care (3, …Keywords
This publication has 6 references indexed in Scilit:
- Maturation of CGM and Glycemic Measurements Beyond HbA1c—A Turning Point in Research and Clinical DecisionsDiabetes Care, 2017
- International Consensus on Use of Continuous Glucose MonitoringDiabetes Care, 2017
- Standardizing Clinically Meaningful Outcome Measures Beyond HbA1c for Type 1 Diabetes: A Consensus Report of the American Association of Clinical Endocrinologists, the American Association of Diabetes Educators, the American Diabetes Association, the Endocrine Society, JDRF International, The Leona M. and Harry B. Helmsley Charitable Trust, the Pediatric Endocrine Society, and the T1D ExchangeDiabetes Care, 2017
- Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trialThe Lancet, 2017
- Improving the Clinical Value and Utility of CGM Systems: Issues and RecommendationsDiabetes Care, 2017
- Does A1c consistently reflect mean plasma glucose?Journal of Diabetes, 2010